Janus Kinase Inhibitors in Dermatology : Part 1 - General Considerations and Applications in Vitiligo and Alopecia Areata Inhibidores de JAK: usos en dermatología. Parte 1: generalidades, aplicaciones en vitíligo y en alopecia areata
Garcia-Melendo, C. (Universitat Autònoma de Barcelona)
Cubiró, Xavier (Institut d'Investigació Biomèdica Sant Pau)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Date: |
2021 |
Abstract: |
Dermatologists' interest in the Janus-associated kinase/signal transducers and activators of transcription (JAK/STAT) pathway has been growing as evidence builds to support its key role in the pathogenesis of inflammatory skin diseases. Because certain proinflammatory cytokines use the JAK/STAT pathway for signal transduction, it has become a promising therapeutic target in diseases where selective modulation of the immune system can be useful. We aim to review current knowledge of the JAK/STAT signaling pathway and its role in immune-mediated skin diseases. In the first part of the review we cover the efficacy and safety of oral and topical JAK inhibitors in the treatment of vitiligo and alopecia areata. |
Rights: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. |
Language: |
Castellà |
Document: |
Article de revisió ; recerca ; Versió publicada |
Subject: |
JAK/STAT pathway ;
Janus kinase inhibitors ;
Vitiligo ;
Alopecia areata |
Published in: |
Actas Dermo-Sifiliograficas, Vol. 112 Núm. 6 (junio 2021) , p. 503-515, ISSN 1578-2190 |
DOI: 10.1016/j.ad.2020.12.003
The record appears in these collections:
Research literature >
UAB research groups literature >
Research Centres and Groups (research output) >
Health sciences and biosciences >
Institut de Recerca Sant PauArticles >
Research articlesArticles >
Published articles
Record created 2022-12-16, last modified 2023-11-30